Oral therapy for onychomycosis: An evidence-based review

Daniel Coelho De Sá, Ana Paula Botto Lamas, Antonella Tosti

Research output: Contribution to journalReview articlepeer-review

31 Scopus citations


Introduction: Onychomycosis is a very common fungal infection of the nail apparatus; however, it is very hard to treat, even when the causative agent is identified, and usually requires prolonged systemic antifungal therapy. Until the 1990s, oral treatment options included only griseofulvin and ketoconazole, and the cure rate was very low. New generations of antimycotics, such as fluconazole, itraconazole and terbinafine have improved treatment success. Methods: Literature was identified by performing a PubMed Ovid MEDLINE, Ovid EMBASE, EBSCO CINAHL, and Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS) search. Prospective and randomized clinical trials were chosen to be included in this review. Forty-six trials were included. Results: Fluconazole, itraconazole and terbinafine are effective in the treatment of onychomycosis and have a good safety profile. When a dermatophyte is the pathogen, terbinafine produces the best results. For Candida and nondermatophyte infections, the azoles, mainly itraconazole, are the recommended therapy. Conclusion: In the majority of the studies, terbinafine treatment showed a higher cure ratio than the other drugs for dermatophyte onychomycosis.

Original languageEnglish (US)
Pages (from-to)17-36
Number of pages20
JournalAmerican Journal of Clinical Dermatology
Issue number1
StatePublished - Feb 1 2014

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Oral therapy for onychomycosis: An evidence-based review'. Together they form a unique fingerprint.

Cite this